Ebselen Enrolling by Invitation Phase 2 Trials for Ototoxicity Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02819856SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity